A detailed history of Charles Schwab Investment Management Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 234,191 shares of JANX stock, worth $11.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
234,191
Previous 77,516 202.12%
Holding current value
$11.8 Million
Previous $3.25 Million 227.66%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$35.29 - $50.26 $5.53 Million - $7.87 Million
156,675 Added 202.12%
234,191 $10.6 Million
Q2 2024

Aug 12, 2024

BUY
$35.12 - $64.78 $992,420 - $1.83 Million
28,258 Added 57.37%
77,516 $3.25 Million
Q1 2024

May 08, 2024

BUY
$7.93 - $49.75 $24,717 - $155,070
3,117 Added 6.76%
49,258 $1.85 Million
Q4 2023

Feb 06, 2024

SELL
$5.85 - $11.7 $15,262 - $30,525
-2,609 Reduced 5.35%
46,141 $495,000
Q3 2023

Nov 08, 2023

BUY
$9.56 - $14.0 $25,133 - $36,806
2,629 Added 5.7%
48,750 $491,000
Q2 2023

Aug 09, 2023

BUY
$11.08 - $15.92 $8,077 - $11,605
729 Added 1.61%
46,121 $547,000
Q1 2023

May 11, 2023

SELL
$11.25 - $22.21 $25,852 - $51,038
-2,298 Reduced 4.82%
45,392 $549,000
Q4 2022

Feb 13, 2023

BUY
$11.1 - $18.26 $12,509 - $20,579
1,127 Added 2.42%
47,690 $628,000
Q3 2022

Nov 14, 2022

BUY
$10.82 - $16.84 $43,853 - $68,252
4,053 Added 9.53%
46,563 $631,000
Q2 2022

Aug 15, 2022

SELL
$9.52 - $15.65 $17,992 - $29,578
-1,890 Reduced 4.26%
42,510 $520,000
Q1 2022

May 13, 2022

BUY
$13.24 - $20.24 $138,410 - $211,588
10,454 Added 30.8%
44,400 $637,000
Q4 2021

Feb 11, 2022

BUY
$15.44 - $27.32 $21,152 - $37,428
1,370 Added 4.21%
33,946 $670,000
Q3 2021

Nov 16, 2021

BUY
$20.7 - $34.69 $674,323 - $1.13 Million
32,576 New
32,576 $705,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.1B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.